Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of Intranasal Nalmefene

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 55 years inclusive~* BMI ranging from 18 to 32 kg/m2, inclusive~* Adequate venous access~* Healthy subjects and non-dependent who are non dependent opioid experienced users, opioid experience defined as exposure to an opioid on at least 1 occasion prior to screening~Exclusion Criteria:~* History of clinically significant disease~* Significant trauma injury, major surgery, open biopsy within 30 days prior to screening~* Subject who has a difficult airway for intubation.~* Following an abnormal diet 4 weeks prior to screening~* Use of over-the-counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention~* Use of enzyme altering drugs 30 days before intervention~* Use of nasal products 28 days before intervention and throughout the study~* Previous or current opioid, alcohol, or other drug dependence~* Donated or received blood 30 days before intervention~* Women who are pregnant or breastfeeding at screening~* Women of childbearing potential unless surgically sterile or use effective contraception~* Current or recent upper respiratory tract infection~* Allergic to nalmefene or naloxone or known hypersensitivity reaction to plastics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Nalmefene (Type: EXPERIMENTAL): Nalmefene hydrochloride nasal spray, 3mg, 1 spray
- Intranasal Naloxone (Type: ACTIVE_COMPARATOR): Naloxone hydrochloride nasal spray, 4mg, 1 spray

Based on this trial design, predict the completion outcome and termination type (if applicable).